The effects of Tim‑3 activation on T‑cells in gastric cancer progression

Yu, Jiangtao; Zhang, Huanhu; Sun, Shengbo; Sun, Shaoli; Li, Leping

doi:10.3892/ol.2018.9743

Cited by 14 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tim-3 plays a key role in inhibiting Th1 response and the expression of cytokines such as TNF and IFN-γ. A number of preclinical reports have demonstrated that Treg strongly expressing TIM-3 have higher immunosuppressive function than TIM-3-negative Treg, because of their increased production of IL-10 and other suppressive molecules [13,14]. Stimulation of TIM-3 on the cell membrane of Treg may happen through its interaction with the Galectin-9, which is expressed by different tumor cells [15].…”

Section: Immune System and Cancermentioning

confidence: 99%

Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy

Perri

Ionna

Longo

et al. 2020

Translational Oncology

View full text Add to dashboard Cite

Head and neck carcinoma (HNC) are diseases arising from several tracts of the aerodigestive ways. Most HNC are squamous cell carcinoma (SCCHN). Immunotherapy is a treatment strategy aimed to reinforce the immune system. Several types of immunotherapy are available in the clinical scenario. Checkpoint inhibitors were developed later in SCCHN; nivolumab and pembrolizumab have reached the clinical approval, having both drugs demonstrated to significantly improve the overall survival, if compared with the standard of treatment (according to the results of the CheckMate 141 and KEYNOTE-040 trials). Nevertheless, immunotherapy may fail because of the genetics of SCCHN. In fact, two genetically different types of SCCHN have been discovered, one virus-related (HPV) and the other mutagens-related. They seem to show in clinical trials very different responses to immunotherapy. Given the existence of a number of factors predictive of response to immunotherapy in SCCHN, a future clinical approach may be to characterize the genetic and immunologic feature of SCCHN and to perform a well-tailored immunotherapy. This review will summarize the main immunotherapy strategies available in SCCHN, discussing their real efficacy, highlighting also the ways to improve them.

show abstract

Section: Immune System and Cancermentioning

confidence: 99%

Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy

Perri

Ionna

Longo

et al. 2020

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Further research explored whether the depletion of TIM-3 could restrain several signal transduction pathways, including the snail, p-GSK-3β and p-AKT pathways ( 92 ). In addition, some studies have suggested that the increased expression of TIM-3 on T cells may be partially responsible for the development of GC by inducing the secretion of IFN-γ and TNF-α ( 93 ). Another study has shown that reduced TIM-3 expression induced by genetic polymorphisms of TIM-3 may promote CRC invasion and metastasis ( 94 ).…”

Section: Immunotherapeutic Strategies In Gastrointestinal Cancer: the Current Scenario And Future Perspectivesmentioning

confidence: 99%

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications

Wang

Zuo

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Gastrointestinal cancer is a leading cause of cancer-related mortality and remains a major challenge for cancer treatment. Despite the combined administration of modern surgical techniques and chemoradiotherapy (CRT), the overall 5-year survival rate of gastrointestinal cancer patients in advanced stage disease is less than 15%, due to rapid disease progression, metastasis, and CRT resistance. A better understanding of the mechanisms underlying cancer progression and optimized treatment strategies for gastrointestinal cancer are urgently needed. With increasing evidence highlighting the protective role of immune responses in cancer initiation and progression, immunotherapy has become a hot research topic in the integrative management of gastrointestinal cancer. Here, an overview of the molecular understanding of colorectal cancer, esophageal cancer and gastric cancer is provided. Subsequently, recently developed immunotherapy strategies, including immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, tumor vaccines and therapies targeting other immune cells, have been described. Finally, the underlying mechanisms, fundamental research and clinical trials of each agent are discussed. Overall, this review summarizes recent advances and future directions for immunotherapy for patients with gastrointestinal malignancies.

show abstract

“…12 However, the detection rate of PG in GC is low, with a sensitivity of 59.3-72.1% and specificity of 61.8-87.39%. [13][14][15] Therefore, there is a need to identify new serum markers, which, in addition to PG, can improve the diagnostic sensitivity of GC.…”

Section: Introductionmentioning

confidence: 99%

Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis

Chen¹,

Hong²,

et al. 2021

CMAR

View full text Add to dashboard Cite

The present study aimed to evaluate the clinical value of the combined detection of soluble T cell immunoglobulinand mucin domain molecule 3 (sTim-3) and pepsinogen (PG) in sera for gastric cancer (GC) diagnosis. Patients and Methods:The double antibody sandwich method was used to establish a highly sensitive time-resolved fluorescence immunoassay for the detection of sTim-3. Serum sTim-3, PGI, and PGII levels in 149 GC patients (123 first-diagnosis GC patients and 26 post-GC patients), 81 patients with benign gastric disease (BGD), and 73 healthy controls were quantitatively detected. The clinical diagnostic value of the combined detection of sTim-3 and PG in GC was analyzed. Results: Serum sTim-3 levels in GC (20.41 ± 9.55 ng/mL) and BGD (16.50 ± 9.76 ng/mL) patients were significantly higher (P < 0.001) than those in healthy controls (9.22 ± 3.40 ng/mL). Combined detection of sTim-3 and PGI/PGII (AUC: 0.9330, sensitivity: 86.44%, and specificity: 91.78%) showed a high diagnostic value for GC. When the level of PGI/PGII was less than 12.11 and that of sTim-3 was greater than 14.30 ng/mL, the positive rate of the control group was reduced to 0%, and the positive detection rate of GC was 54.47%. In addition, in post-operative patients, serum sTim-3 levels in the recurrence group (33.56 ± 4.91 ng/mL) were significantly higher than those in the no recurrence group (11.95 ± 5.16 ng/mL). Conclusion: sTim-3 levels in BGD and GC sera were significantly higher than those in the control group sera. Additionally, sTim-3 serum levels can predict recurrence in postoperative patients. Compared with PG alone, the combined detection of serum PG and sTim-3 can significantly improve the detection sensitivity and specificity of BGD and GC.

show abstract

The effects of Tim‑3 activation on T‑cells in gastric cancer progression

Cited by 14 publications

References 22 publications

Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy

Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications

Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis

Contact Info

Product

Resources

About